Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new treatment.

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...